Radom Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -1.29%
- Ebitda
- Net Worth -6.36%
- Total Assets -6.11%
About Radom Biosciences
Radom Biosciences Private Limited (RBPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 December 2009 and has a history of 15 years and one month. Its registered office is in Panipat, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Kumar and Motilal Chawla serve as directors at the Company.
Company Details
-
Location
Panipat, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909HR2009PTC039829
-
Company No.
039829
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Dec 2009
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Radom Biosciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar
|
Director | 16-Dec-2009 | Current |
|
Motilal Chawla
|
Director | 16-Dec-2009 | Current |
Financial Performance of Radom Biosciences.
Radom Biosciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 1.29% decrease in profit. The company's net worth dipped by a decrease of 6.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Radom Biosciences?
In 2020, Radom Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Plus Distribution Private LimitedAnil Kumar is a mutual person
-
Anekant Pharmaceuticals Private LimitedAnil Kumar and Motilal Chawla are mutual person
-
Hitarth Enterprises Private LimitedMotilal Chawla is a mutual person
-
Almo Impex (India) Private LimitedAnil Kumar is a mutual person
-
Almo Exports Private Limited
Anil Kumar and Motilal Chawla are mutual person
-
Scarlet Formulation Private Limited
Anil Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Radom Biosciences?
Unlock and access historical data on people associated with Radom Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Radom Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Radom Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
